Aug 26 (Reuters) - BioXcel Therapeutics Inc BTAI.O:
BIOXCEL THERAPEUTICS TO ANNOUNCE TOPLINE RESULTS FROM SERENITY AT-HOME PIVOTAL PHASE 3 SAFETY TRIAL FOR ACUTE TREATMENT OF AGITATION ASSOCIATED WITH BIPOLAR DISORDERS OR SCHIZOPHRENIA ON AUGUST 27, 2025